Your browser doesn't support javascript.
loading
ST6GAL1-mediated aberrant sialylation promotes prostate cancer progression.
Scott, Emma; Archer Goode, Emily; Garnham, Rebecca; Hodgson, Kirsty; Orozco-Moreno, Margarita; Turner, Helen; Livermore, Karen; Putri Nangkana, Kyla; Frame, Fiona M; Bermudez, Abel; Jose Garcia Marques, Fernando; McClurg, Urszula L; Wilson, Laura; Thomas, Huw; Buskin, Adriana; Hepburn, Anastasia; Duxfield, Adam; Bastian, Kayla; Pye, Hayley; Arredondo, Hector M; Hysenaj, Gerald; Heavey, Susan; Stopka-Farooqui, Urszula; Haider, Aiman; Freeman, Alex; Singh, Saurabh; Johnston, Edward W; Punwani, Shonit; Knight, Bridget; McCullagh, Paul; McGrath, John; Crundwell, Malcolm; Harries, Lorna; Heer, Rakesh; Maitland, Norman J; Whitaker, Hayley; Pitteri, Sharon; Troyer, Dean A; Wang, Ning; Elliott, David J; Drake, Richard R; Munkley, Jennifer.
Afiliación
  • Scott E; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Archer Goode E; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Garnham R; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Hodgson K; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Orozco-Moreno M; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Turner H; Cellular Pathology, The Royal Victoria Infirmary, Newcastle upon Tyne, UK.
  • Livermore K; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Putri Nangkana K; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Frame FM; Cancer Research Unit, Department of Biology, University of York, North Yorkshire, UK.
  • Bermudez A; Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, USA.
  • Jose Garcia Marques F; Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, USA.
  • McClurg UL; Institute of Systems, Molecular & Integrative Biology, University of Liverpool, Liverpool, UK.
  • Wilson L; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, UK.
  • Thomas H; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, UK.
  • Buskin A; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, UK.
  • Hepburn A; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, UK.
  • Duxfield A; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Bastian K; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Pye H; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
  • Arredondo HM; The Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
  • Hysenaj G; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Heavey S; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
  • Stopka-Farooqui U; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
  • Haider A; Department of Pathology, UCLH NHS Foundation Trust, London, UK.
  • Freeman A; Department of Pathology, UCLH NHS Foundation Trust, London, UK.
  • Singh S; UCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
  • Johnston EW; UCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
  • Punwani S; UCL Centre for Medical Imaging, Charles Bell House, University College London, London, UK.
  • Knight B; NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • McCullagh P; Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • McGrath J; Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Crundwell M; Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Harries L; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK.
  • Heer R; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, UK.
  • Maitland NJ; Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Whitaker H; Cancer Research Unit, Department of Biology, University of York, North Yorkshire, UK.
  • Pitteri S; Molecular Diagnostics and Therapeutics Group, Charles Bell House, Division of Surgery and Interventional Science, University College London, London, UK.
  • Troyer DA; Canary Center at Stanford for Cancer Early Detection, Department of Radiology, Stanford University, Palo Alto, CA, USA.
  • Wang N; Cancer Biology and Infectious Disease Research Center, Eastern Virginia Medical School, Norfolk, VA, USA.
  • Elliott DJ; The Mellanby Centre for Musculoskeletal Research, Department of Oncology and Metabolism, The University of Sheffield, Sheffield, UK.
  • Drake RR; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK.
  • Munkley J; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, SC, USA.
J Pathol ; 261(1): 71-84, 2023 09.
Article en En | MEDLINE | ID: mdl-37550801
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Sialiltransferasas Tipo de estudio: Prognostic_studies Límite: Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Pathol Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Sialiltransferasas Tipo de estudio: Prognostic_studies Límite: Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Pathol Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido